• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » University of Delaware partners with Fraunhofer USA

University of Delaware partners with Fraunhofer USA

July 18, 2011
CenterWatch Staff

The University of Delaware and biotech company Fraunhofer USA have forged a new six-year partnership the university describes as a win-win-win: a win for the university, a win for Fraunhofer and an economic win for the state of Delaware, according to NewsWorks.

"They're taking research that's coming out of laboratories, like at the University of Delaware, and they have scientists and engineers working on actually converting that into real inventions," said UD’s Dr. Karl Steiner. "And inventions will lead, therefore, to small companies, hopefully bigger companies, that create jobs."

The Newark-based Fraunhofer USA Center for Molecular Biotechnology (CMB) said turning ideas into real products typically takes more than 10 years and hundreds of millions of dollars. But with this new partnership in place, the university and CMB hope to streamline the development process.

Delaware also has a stake in how well CMB performs in the world of bio-based vaccine production. Delaware Economic Development Office Secretary Alan Levin said the state owns 5% of CMB stock and believes combining UD's strengths with Fraunhofer's can only lead to success.

The state has approved a $6 million investment over the six years for CMB, and come September Secretary Levin said he'll recommend to the Council on Development Finance an additional $3 million, which works out to about $1.5 million a year over the six-year timeframe.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing